The Skidki-na-vse® ADHD resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
Raising Awareness for ADHD in October
Seventeen million children and adults in the United States are currently living with ADHD. Each October, ADHD Awareness Month is celebrated with different events, activities, and resources to continue shining the light on the disorder.
Analysis Suggests Stimulant Treatment Prevents Some Outcomes of ADHD
An analysis of previous studies of children and young adults with ADHD has quantified the extent to which stimulant treatment reduces the development of mood disorders, problems in school, conduct disorders, substance use disorders, and other problems.
Study: Teens with ADHD Have a Higher Crash Risk
The study included an analysis detailing crash and traffic violation records for newly licensed drivers. It is the first large-scale longitudinal study on this topic.
ADHD Treatment Strategies Are Based on Evidence
It is critical to stress that Attention-Deficit/Hyperactivity Disorder is probably a lifelong condition for most individuals with the condition.
March 29 Pharmacy Week in Review: Study Evaluates Risk of Psychosis in Young Patients with ADHD, Long-Term Survival May Be Associated with MS Treatment
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Study: Certain ADHD Medications May Increase the Risk of Psychosis
The prescription of stimulants for the treatment of attention deficit-hyperactivity disorder (ADHD) is increasing among adolescents and young adults, and a new study sheds light on possible safety concerns.
Adhansia XR Gets FDA Nod for ADHD Treatment
The drug's approval was based on 4 clinical studies evaluating the efficacy and safety of Adhansia XR in 883 people who met DSM-5 criteria for ADHD.  
Researchers: Gene Involved in ADHD Could Be Related to Addictive Substance Use
Within the group of Spanish patients with ADHD, a specific variation of the LPHN3 gene increased by 40% the risk of nicotine dependence.
Neos Settles with Teva Over ADHD Drug
Under the settlement and license agreement, Neos has granted Teva the right to manufacture and market its generic version of Cotempla XR-ODT® under the Teva ANDA beginning on July 1, 2026, or earlier under certain circumstances.
Study: Therapy Dogs Reduce ADHD Symptoms in Children
Canine animal assistance improves attentiveness and social skills in children with ADHD, according to recent study.
+ Load More

дженерик виагра купить в украине

пилинг лица киев